Instil Bio (TIL) Company Report

Instil Bio reported $83.4 million in cash, cash equivalents, restricted cash, marketable securities, and long-term investments as of September 30, 2025, which is expected to fund its operating plan beyond 2026.
The company's net loss per share for the third quarter ended September 30, 2025, was $2.01, compared to $3.54 for the same period in 2024.
In October 2025, Instil's subsidiary, Axion Bio, dosed the first patient in its Phase 1 clinical trial evaluating AXN-2510/IMM2510 monotherapy in adult patients with advanced solid tumors.
Research and development expenses increased to $9.1 million for the three months ended September 30, 2025, from $0.6 million in the prior year period, while general and administrative expenses decreased to $5.9 million from $10.7 million over the same periods.

Nov 13, 2025, 12:05 PM

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

TIL

Earnings

Guidance Update

New Projects/Investments

Instil Bio reported its third quarter 2025 financial results and provided a corporate update on November 13, 2025.
As of September 30, 2025, Instil had $83.4 million in cash, cash equivalents, restricted cash, marketable securities, and long-term investments, which is expected to fund its operating plan beyond 2026.
The company reported a net loss per share of $2.01 for the three months ended September 30, 2025, compared to $3.54 for the same period in 2024.
In October, Instil's subsidiary, Axion Bio, dosed the first patient in its Phase 1 clinical trial of ‘2510 as monotherapy in patients with relapsed or refractory solid tumors.

Nov 13, 2025, 12:00 PM

Earnings Transcripts

Quarterly earnings call transcripts for Instil Bio.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop